INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Public company

BMYBRISTOL MYERS SQUIBB CO

CIK 0000014272

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 3
Max Insider Score35
Connections27with evidence

BMY · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
17
LA
Lenkowsky AdamEVP, Chief Commercial Officer
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
7,522 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Connected organizationevidence
    BRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEEFEC Form 1 connected organization: BRISTOL-MYERS SQUIBB COMPANY (curated map) · Nov 4, 2026
  • ← Insider ofevidence
    Meyers Gregory ScottEVP, Chief Digital & Tech Off. · Nov 3, 2026
  • ← Insider ofevidence
    Shanahan KarinEVP, Chief Supply Chain & Ops · Nov 3, 2026
21
LA
Lenkowsky AdamEVP, Chief Commercial Officer
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M
—
7,522 sh
Nov 3, 2026
Nov 4, 2026
traded Nov 3, 2026
+1d
SEC FORM 4

Evidence

16
LA
Lenkowsky AdamEVP, Chief Commercial Officer
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$237K
3,848 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC FORM 4

Evidence

16
MS
Meyers Gregory ScottEVP, Chief Digital & Tech Off.
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$167K
2,665 sh
Nov 1, 2026Nov 3, 2026
traded Nov 1, 2026
+2dSEC FORM 4

Evidence

17
SK
Shanahan KarinEVP, Chief Supply Chain & Ops
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
6,281 sh
Nov 1, 2026Nov 3, 2026
traded Nov 1, 2026
+2dSEC FORM 4

Evidence

16
SK
Shanahan KarinEVP, Chief Supply Chain & Ops
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$201K
3,213 sh
Nov 1, 2026Nov 3, 2026
traded Nov 1, 2026
+2dSEC FORM 4

Evidence

9
SK
Shanahan KarinEVP, Chief Supply Chain & Ops
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
6,281 sh
Nov 1, 2026Nov 3, 2026
traded Nov 1, 2026
+2dSEC FORM 4

Evidence

17
MS
Meyers Gregory ScottEVP, Chief Digital & Tech Off.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
6,281 sh
Nov 1, 2026Nov 3, 2026
traded Nov 1, 2026
+2dSEC FORM 4

Evidence

9
MS
Meyers Gregory ScottEVP, Chief Digital & Tech Off.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
6,281 sh
Nov 1, 2026Nov 3, 2026
traded Nov 1, 2026
+2dSEC FORM 4

Evidence

9
GC
Gallman CariEVP, General Counsel
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
4,559 sh
Oct 2, 2026Oct 5, 2026
traded Oct 2, 2026
+3dSEC FORM 4

Evidence

16
GC
Gallman CariEVP, General Counsel
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$143K
2,332 sh
Oct 2, 2026Oct 5, 2026
traded Oct 2, 2026
+3dSEC FORM 4

Evidence

17
GC
Gallman CariEVP, General Counsel
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
4,559 sh
Oct 2, 2026Oct 5, 2026
traded Oct 2, 2026
+3dSEC FORM 4

Evidence

35
MC
Massacesi CristianEVP,Chief Med Offr,Head of Dev
BMYBRISTOL MYERS SQUIBB CO
Open-market sale
SELL$403K
6,249 sh
Sep 9, 2026Sep 10, 2026
traded Sep 9, 2026
+1dSEC FORM 4

Evidence

13
SW
Short Bartie WendyEVP, Corporate Affairs
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$42K
633 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

16
SW
Short Bartie WendyEVP, Corporate Affairs
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M$83K
1,236 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

9
SW
Short Bartie WendyEVP, Corporate Affairs
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
1,236 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

21
HM
Holzer Phil MSVP and Controller
BMYBRISTOL MYERS SQUIBB CO
Open-market sale
SELL$34K
500 sh
Aug 25, 2026Aug 26, 2026
traded Aug 25, 2026
+1dSEC FORM 4

Evidence

28
Mike KellyRSpouse
BMYBRISTOL MYERS SQUIBB CO
Sale
SELL$15K – $50KMay 7, 2026Jun 11, 2026
traded May 7, 2026
+35dHOUSE PTR

Evidence

20
SW
Short Bartie WendyEVP, Corporate Affairs
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$212K
3,876 sh
Jun 3, 2026Jun 5, 2026
traded Jun 3, 2026
+2dSEC FORM 4

Evidence

9
SW
Short Bartie WendyEVP, Corporate Affairs
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
8,040 sh
Jun 3, 2026Jun 5, 2026
traded Jun 3, 2026
+2dSEC FORM 4

Evidence

21
SW
Short Bartie WendyEVP, Corporate Affairs
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
8,040 sh
Jun 3, 2026Jun 5, 2026
traded Jun 3, 2026
+2dSEC FORM 4

Evidence

12
LA
Lenkowsky AdamEVP, Chief Commercial Officer
BMYBRISTOL MYERS SQUIBB CO
Other acquisition or disposition
J—
203 sh
May 1, 2026May 5, 2026
traded May 1, 2026
+4dSEC FORM 4

Evidence

21
LA
Lenkowsky AdamEVP, Chief Commercial Officer
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
1,373 sh
May 1, 2026May 5, 2026
traded May 1, 2026
+4dSEC FORM 4

Evidence

13
LA
Lenkowsky AdamEVP, Chief Commercial Officer
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
1,373 sh
May 1, 2026May 5, 2026
traded May 1, 2026
+4dSEC FORM 4

Evidence

9
LA
Lenkowsky AdamEVP, Chief Commercial Officer
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$35K
599 sh
May 1, 2026May 5, 2026
traded May 1, 2026
+4dSEC FORM 4

Evidence

17
HM
Holzer Phil MSVP and Controller
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
4,612 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

16
HM
Holzer Phil MSVP and Controller
BMYBRISTOL MYERS SQUIBB CO
Other acquisition or disposition
J—
2,264 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

16
HM
Holzer Phil MSVP and Controller
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$51K
849 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HM
Holzer Phil MSVP and Controller
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
811 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

21
HM
Holzer Phil MSVP and Controller
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
768 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HM
Holzer Phil MSVP and Controller
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
4,612 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HM
Holzer Phil MSVP and Controller
BMYBRISTOL MYERS SQUIBB CO
Grant or award
A—
5,031 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HM
Holzer Phil MSVP and Controller
BMYBRISTOL MYERS SQUIBB CO
Grant or award
A—
7,547 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

13
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
838 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

12
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Other acquisition or disposition
J—
94 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$13K
212 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

17
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
1,050 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

12
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Other acquisition or disposition
J—
113 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$16K
267 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

21
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
6,304 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

24
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Other acquisition or disposition
J—
3,095 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

16
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$55K
912 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
838 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

21
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
1,050 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
6,304 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Grant or award
A—
6,531 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Grant or award
A—
9,796 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

13
PA
Poole Ahn AmandaEVP, Chief People Officer
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
811 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

12
PA
Poole Ahn AmandaEVP, Chief People Officer
BMYBRISTOL MYERS SQUIBB CO
Other acquisition or disposition
J—
91 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

13
PA
Poole Ahn AmandaEVP, Chief People Officer
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$22K
369 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

13
PA
Poole Ahn AmandaEVP, Chief People Officer
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
803 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

12
PA
Poole Ahn AmandaEVP, Chief People Officer
BMYBRISTOL MYERS SQUIBB CO
Other acquisition or disposition
J—
87 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

13
PA
Poole Ahn AmandaEVP, Chief People Officer
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$22K
367 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

21
PA
Poole Ahn AmandaEVP, Chief People Officer
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
4,822 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

20
PA
Poole Ahn AmandaEVP, Chief People Officer
BMYBRISTOL MYERS SQUIBB CO
Other acquisition or disposition
J—
2,368 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

20
PA
Poole Ahn AmandaEVP, Chief People Officer
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$76K
1,256 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
PA
Poole Ahn AmandaEVP, Chief People Officer
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
811 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

21
PA
Poole Ahn AmandaEVP, Chief People Officer
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
803 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
PA
Poole Ahn AmandaEVP, Chief People Officer
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
4,822 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
PA
Poole Ahn AmandaEVP, Chief People Officer
BMYBRISTOL MYERS SQUIBB CO
Grant or award
A—
15.3K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

  • ← Lobbied forevidence
    W STRATEGIES, LLCLDA RR 2026 first quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    THE MCMANUS GROUPLDA Q2 2026 second quarter · Medicare/Medicaid, Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    ALEXANDER J. BECKLES, L.L.C.LDA RR 2026 first quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    MARSHALL & POPP, LLCLDA RR 2026 first quarter · Pharmacy, Trade · Aug 26, 2026
  • ← Lobbied forevidence
    CAPITOL COUNSEL LLCLDA RR 2026 first quarter · Health issues, MED, Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    MILLER STRATEGIES, LLCLDA Q2 2026 second quarter · Health issues, Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    TARPLIN, DOWNS & YOUNG, LLCLDA Q1 2026 first quarter · Medicare/Medicaid, Health issues, Budget/appropriations · Aug 26, 2026
  • ← Lobbied forevidence
    AVENUE SOLUTIONSLDA Q1 2026 first quarter · Health issues, Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    CROSSROADS STRATEGIES, LLCLDA 1TY 2026 first quarter · issues not listed · Aug 26, 2026
  • ← Lobbied forevidence
    TODD STRATEGY GROUPLDA Q1 2026 first quarter · Health issues, Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    WILLIAMS AND JENSEN, PLLCLDA Q1 2026 first quarter · Health issues, Medicare/Medicaid, Trade, Pharmacy · Aug 26, 2026
  • ← Lobbied forevidence
    ADVANCED POLICY CONSULTING, LLCLDA RR 2026 third quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    SPLITOAK STRATEGIES LLCLDA Q2 2026 second quarter · Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    FEDERAL STREET STRATEGIES, LLCLDA Q1 2026 first quarter · Health issues · Aug 26, 2026
  • ← Disclosed trade inevidence
    Mike KellySale disclosed 2026-06-11 · Jun 11, 2026
  • ← Insider ofevidence
    Gallman CariEVP, General Counsel · Mar 12, 2026
  • ← Insider ofevidence
    Shibutani Hiroshi ChrisEVP, Chief Strategy Officer · Mar 12, 2026
  • ← Insider ofevidence
    Hoch LynellePresident, Cell Therapy Org. · Mar 12, 2026
  • ← Insider ofevidence
    Poole Ahn AmandaEVP, Chief People Officer · Mar 12, 2026
  • ← Insider ofevidence
    Holzer Phil MSVP and Controller · Mar 12, 2026
  • ← Insider ofevidence
    Lenkowsky AdamEVP, Chief Commercial Officer · Mar 12, 2026
  • ← Insider ofevidence
    Massacesi CristianEVP,Chief Med Offr,Head of Dev · Mar 12, 2026
  • ← Insider ofevidence
    Short Bartie WendyEVP, Corporate Affairs · Mar 12, 2026

    • Lobbying

    $4.48M reported · de-duplicated
    2026 Q3 $0 via firms2026 Q2 $3.16M in-house2026 Q1 $1.32M in-house
    • SPLITOAK STRATEGIES LLC$60K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid
    • FEDERAL STREET STRATEGIES, LLC$50K2026 Q2 · posted Aug 26, 2026 · Health issues
    • AVENUE SOLUTIONS—2026 Q1 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid
    • FEDERAL STREET STRATEGIES, LLC$50K2026 Q1 · posted Aug 26, 2026 · Health issues
    • WILLIAMS AND JENSEN, PLLC$80K2026 Q2 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid, Trade, Pharmacy
    • THE MCMANUS GROUP$80K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid
    • W STRATEGIES, LLC—2026 Q1 · posted Aug 26, 2026 · Health issues
    • ALEXANDER J. BECKLES, L.L.C.$20K2026 Q1 · posted Aug 26, 2026 ·
    • MARSHALL & POPP, LLC$60K2026 Q2 · posted Aug 26, 2026 · Pharmacy
    • WILLIAMS AND JENSEN, PLLC$80K2026 Q1 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid, Trade, Pharmacy
    • CAPITOL COUNSEL LLC$40K2026 Q1 · posted Aug 26, 2026 · Health issues, MED, Medicare/Medicaid
    • W STRATEGIES, LLC$50K2026 Q2 · posted Aug 26, 2026 · Health issues

    Connected PAC contributions

    FEC · direct to members
    • John JoyceR$10KBRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEE
    • Jason SmithR$10KBRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEE
    • Suzan K. DelBeneD$10KBRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEE
    • Brett GuthrieR$10KBRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEE
    • Diana HarshbargerR$10KBRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEE
  • Brian JackR$9,000BRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEE
  • Richard HudsonR$8,000BRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEE
  • Brendan F. BoyleD$7,500BRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEE
  • Bradley Scott SchneiderD$7,000BRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEE
  • H. Morgan GriffithR$6,000BRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEE
  • Darin LaHoodR$6,000BRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEE
  • Thomas H. Kean, Jr.R$6,000BRISTOL-MYERS SQUIBB COMPANY POLITICAL ACTION COMMITTEE